ABSTRACT
Background Smooth muscle cells (SMCs), which make up the medial layer of arteries, are key cell types involved in cardiovascular diseases (CVD), the leading cause of mortality and morbidity worldwide. In response to microenvironment alterations, SMCs dedifferentiate from a “contractile” to a “synthetic” phenotype characterized by an increased proliferation, migration, production of extracellular matrix (ECM) components, and decreased expression of SMC-specific contractile markers. These phenotypic changes result in vascular remodeling and contribute to the pathogenesis of CVD, including coronary artery disease (CAD), stroke, hypertension, and aortic aneurysms. Here, we aim to identify the genetic variants that regulate ECM secretion in SMCs and predict the causal proteins associated with vascular disease-related loci identified in genome-wide association studies (GWAS).
Methods Using human aortic SMCs from 123 multi-ancestry healthy heart transplant donors, we collected the serum-free media in which the cells were cultured for 24 hours and conducted Liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based proteomic analysis of the conditioned media.
Results We measured the abundance of 270 ECM and related proteins. Next, we performed protein quantitative trait locus mapping (pQTL) and identified 20 loci associated with secreted protein abundance in SMCs. We functionally annotated these loci using a colocalization approach. This approach prioritized the genetic variant rs6739323-A at the 2p22.3 locus, which is associated with lower expression of LTBP1 in SMCs and atherosclerosis-prone areas of the aorta, and increased risk for SMC calcification. We found that LTBP1 expression is abundant in SMCs, and its expression at mRNA and protein levels was reduced in unstable and advanced atherosclerotic plaque lesions.
Conclusions Our results unravel the SMC proteome signature associated with vascular disorders, which may help identify potential therapeutic targets to accelerate the pathway to translation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by an American Heart Association Postdoctoral Fellowship 18POST33990046 (to R.A.), the University of Eastern Finland (Researcher Fellowship, to RA), Transformational Project Award 19TPA34910021 (to M.C.), National Institutes of Health Grants: R21HL135230 (to M.C.), Academy of Finland (Grant No's 333021 and 335973 to M.U.K), R01 HL155165 (to G.K.O.), European Research Council Horizon 2020 Research and Innovation Programme (Grant No. 802825 to M.U.K), the Finnish Foundation for Cardiovascular Research (to M.U.K), The Sigrid Juselius Foundation (to M.U.K) and Transatlantic Network of Excellence Awards (12CVD02, 18CVD02) from Foundation Leducq (to G.K.O, A.F., M.M., and M.C.) and its Junior Investigator Award (to R.A., and F.B). N.M. is a British Heart Foundation (BHF) Chair Holder (CH/16/3/32406) with BHF programme grant support (RG/16/14/32397). K.T. and M.M. were also supported with a BHF programme grant (RG/20/10387). M.M. is also supported by the VASCage: Research Center on Vascular Ageing and Stroke (No. 868624).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of Virginia Institutional Review Board decided that the samples used in this manuscript are exempt from Human Subjects Research rules because they are isolated from deceased people. The Institutional Review Board at CVPath Institute (Gaithersburg, Maryland) approved this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
RNAseq data are available at GEO with the accession numbers GSE193817. eQTL results can be accessed at https://virginia.box.com/s/t5e1tzlaqsf85z13o4ie2f9t1i0zfypd and User-friendly website at http://civeleklab.cphg.virginia.edu to query the dataset published in this paper.
